PT-141 (Bremelanotide) vs AOD-9604: Head-to-Head Efficacy Comparison

Why These Two Peptides Get Compared

Patients exploring peptide therapy through telehealth platforms often encounter both PT-141 and AOD-9604 on the same pharmacy menu. That proximity creates confusion. The two compounds share a subcutaneous injection route, a peptide backbone, and a reputation as "specialty" therapies outside mainstream prescribing. The similarity ends there.

PT-141 (generic name: bremelanotide) acts on melanocortin-4 receptors in the hypothalamus to increase sexual desire 1. AOD-9604 is a 16-amino-acid fragment corresponding to residues 176 through 191 of human growth hormone, designed to reproduce growth hormone's fat-burning effect without triggering IGF-1 release or the diabetogenic actions of full-length hGH 2. One treats a sexual health condition. The other targets adiposity. Comparing their "efficacy" requires evaluating each on its own primary endpoint, then contrasting the strength and maturity of the evidence behind each claim.

The distinction matters for informed consent. A patient prescribed one peptide should understand why the other would never substitute for it, even though both arrive in similar vials from the same compounding pharmacy.

Mechanism of Action: Two Unrelated Pathways

PT-141 binds melanocortin-3 and melanocortin-4 receptors (MC3R/MC4R) in the central nervous system, activating downstream signaling that modulates dopaminergic and oxytocinergic circuits tied to sexual arousal 3. It was derived from the synthetic peptide melanotan II but engineered to reduce melanogenic (skin-tanning) activity while preserving pro-sexual effects. The 2016 FDA pharmacology review confirmed that bremelanotide increases sexual desire through a CNS-mediated mechanism distinct from peripheral vasodilators like PDE5 inhibitors 4.

AOD-9604 works peripherally. Heffernan and colleagues demonstrated in 2001 that the C-terminal fragment of hGH stimulates lipolysis in adipose tissue of obese Zucker rats without activating the growth hormone receptor's full signaling cascade 2. The fragment increased fat oxidation and reduced weight gain over a 19-day treatment period. Proposed mechanisms include activation of the beta-3 adrenergic receptor pathway in adipocytes, though the exact receptor target in humans has not been confirmed by an independent group 5.

These pathways do not intersect. A patient using PT-141 for low desire will not experience fat-loss effects; a patient injecting AOD-9604 will not notice changes in libido.

PT-141 Clinical Evidence: The RECONNECT Program

The strongest evidence for bremelanotide comes from the RECONNECT trials, two identically designed phase 3, randomized, double-blind, placebo-controlled studies in premenopausal women diagnosed with HSDD 1.

Across both studies, 1,247 women self-administered bremelanotide 1.75 mg subcutaneously on an as-needed basis (at least 45 minutes before anticipated sexual activity) for 24 weeks. The co-primary endpoints were change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score and the Female Sexual Function Index (FSFI) desire domain score.

Results were statistically significant on both endpoints. The FSDS-DAO Item 13 score (measuring distress from low desire) decreased by 0.7 points more in the bremelanotide group than in the placebo group (P<0.001). The FSFI desire domain score improved by 0.5 points over placebo (P<0.001) 1. Dr. Sheryl Kingsberg, lead investigator on the RECONNECT program, stated: "Bremelanotide represents the first on-demand treatment for HSDD that women can self-administer, and the results show a meaningful reduction in distress associated with low sexual desire" 1.

The effect size was modest but consistent. Roughly 50% of bremelanotide-treated women reported a clinically meaningful improvement in desire, versus 36% on placebo. Nausea was the most common adverse event at 40% (versus 1% placebo), though it typically diminished by the second or third dose 4.

The FDA approved bremelanotide (brand name Vyleesi) in June 2019 for premenopausal women with acquired, generalized HSDD, making it the second FDA-approved drug for this indication after flibanserin 4.

AOD-9604 Clinical Evidence: Preclinical Promise, Thin Human Data

AOD-9604's evidence base is substantially less mature. The foundational work by Heffernan et al. (2001) showed that obese Zucker rats treated with AOD-9604 at 500 mcg/kg/day for 19 days exhibited a 50% reduction in weight gain compared to vehicle-treated controls, with no change in IGF-1 levels or blood glucose 2. A follow-up study by the same group confirmed lipolytic activity in human adipose tissue explants in vitro 5.

Human trial data is sparse. An Australian biotechnology company (Metabolic Pharmaceuticals) conducted a phase 2b oral-dose study of AOD-9604 in approximately 300 obese adults in the mid-2000s. The primary endpoint was change in body weight at 12 weeks. Results were not published in a peer-reviewed journal, and the company disclosed in investor communications that the trial did not meet its primary endpoint 6. The oral formulation may have been a limiting factor, as subcutaneous delivery bypasses first-pass metabolism.

No phase 3 trial for AOD-9604 has been registered on ClinicalTrials.gov. The peptide has no FDA-approved indication, no monograph in the FDA Orange Book, and no compendial listing in the United States Pharmacopeia. It is available through 503A and 503B compounding pharmacies in the United States, typically prescribed off-label for fat reduction by telehealth and anti-aging clinics.

The Endocrine Society's 2009 clinical practice guideline on growth hormone use in adults does not mention AOD-9604, and no major endocrine or obesity society has issued a position statement on the peptide 7.

Efficacy Comparison: Apples to Airplanes

Placing these two peptides in a single efficacy table exposes how different their evidence profiles are. A useful comparison requires grading each peptide on three dimensions: endpoint validation, trial rigor, and regulatory recognition.

Endpoint validation. PT-141's co-primary endpoints (FSDS-DAO Item 13 and FSFI desire domain) are psychometrically validated instruments accepted by the FDA's Division of Bone, Reproductive and Urologic Products for HSDD trials 4. AOD-9604's primary endpoint in the only known human RCT was body weight change, a standard obesity endpoint, but the trial failed to show significance.

Trial rigor. PT-141 has two adequately powered phase 3 RCTs totaling 1,247 patients with 24 weeks of follow-up. AOD-9604 has strong preclinical data in rodents, one published in-vitro human tissue study, and one phase 2b RCT that did not meet its endpoint and was never published in full.

Regulatory recognition. PT-141 holds an NDA (210557) and is commercially available as Vyleesi. AOD-9604 has no NDA, no IND publicly listed, and no FDA letter of non-objection for compounding.

The gap is not a close call. One peptide has crossed every regulatory threshold the FDA requires. The other has not cleared the most basic efficacy bar in a controlled human trial.

Safety and Side-Effect Profiles

Both peptides have documented side effects, though the data quality differs by orders of magnitude.

PT-141's safety database includes over 3,600 patients across phase 2 and phase 3 trials 4. Nausea is the dominant adverse event, reported by roughly 40% of patients after the first dose but declining to approximately 22% by the eighth dose. Flushing occurred in 20% of patients. The FDA label includes a precaution about transient increases in blood pressure (mean systolic rise of 3 mmHg within 2 to 3 hours post-dose) and a recommendation against use in patients with uncontrolled hypertension or cardiovascular disease. Focal hyperpigmentation was reported in 1% of patients. No serious cardiovascular events were attributed to bremelanotide in the clinical program.

The FDA label explicitly states: "Vyleesi is not recommended for use more than once within 24 hours or more than 8 times per month due to the potential for blood pressure increases" 4.

AOD-9604's human safety data is limited to the unpublished phase 2b trial and anecdotal clinic-level reporting. Preclinical studies in rats showed no adverse effects on glucose tolerance, insulin sensitivity, or IGF-1 at the doses tested 2. Anecdotal reports from compounding-pharmacy patients describe injection-site reactions, headache, and gastrointestinal discomfort, but no systematic safety review has been published. The lack of a large safety database is itself a risk factor.

Dosing, Administration, and Practical Considerations

PT-141 is supplied as a single-dose, 1.75 mg/0.3 mL auto-injector (Vyleesi) or as a compounded subcutaneous injection. Patients inject into the abdomen or thigh at least 45 minutes before anticipated sexual activity 4. Maximum dosing: once in 24 hours, no more than 8 doses per calendar month. There is no titration schedule. Onset of effect is typically 30 to 60 minutes, and the effect duration reported by patients ranges from 2 to 6 hours.

AOD-9604 has no FDA-approved dose. Compounding pharmacies typically supply it in multi-dose vials at concentrations of 2 to 5 mg/mL. Clinics commonly prescribe 250 to 300 mcg subcutaneously once daily, administered in the morning on an empty stomach, with treatment durations of 8 to 12 weeks. None of these dosing parameters have been validated in a published, peer-reviewed human efficacy trial.

The practical difference is significant. A prescriber using PT-141 can reference an FDA-approved label with pharmacokinetic data, dose-response curves, and drug-interaction tables. A prescriber using AOD-9604 is relying on preclinical extrapolation and clinic consensus, neither of which constitutes Level 1 evidence per the Oxford Centre for Evidence-Based Medicine hierarchy 8.

Who Is a Candidate for Each Peptide

PT-141 is indicated for premenopausal women with acquired, generalized HSDD not explained by a coexisting medical or psychiatric condition, relationship factors, or medication effects 4. Off-label use in men with erectile dysfunction unresponsive to PDE5 inhibitors has been explored in small trials (N=289, phase 2), with reported improvements in erectile function scores, though this use remains off-label and lacks phase 3 data 9.

AOD-9604 is used off-label for patients seeking fat reduction who prefer peptide-based therapy over GLP-1 receptor agonists or who have contraindications to semaglutide and tirzepatide. Candidates are typically adults with BMI 27 to 35 who want modest fat loss without appetite suppression. No guideline from the Endocrine Society, the American Association of Clinical Endocrinologists, or the Obesity Medicine Association recommends AOD-9604 for weight management 10.

A patient could theoretically use both peptides simultaneously for different goals (sexual health and fat loss), though no study has evaluated the combination, and prescribers should check for overlapping cardiovascular risk.

Cost and Access Through Telehealth

Vyleesi (brand-name PT-141) carries a list price of approximately $950 per auto-injector kit (4 doses). Insurance coverage is inconsistent; many plans classify HSDD treatments as lifestyle medications and deny coverage. Compounded bremelanotide from 503B pharmacies typically costs $100 to $250 per month depending on dose frequency 4.

Compounded AOD-9604 costs $100 to $300 per month for a 30-day supply at commonly prescribed doses. No insurance plan covers AOD-9604 because it lacks an approved indication and an NDC code associated with an NDA. Both peptides are available through HealthRX's telehealth platform after a clinical evaluation confirming the appropriate indication and ruling out contraindications.

The Evidence Gap Matters for Informed Consent

The asymmetry in data quality between these two peptides should be disclosed to every patient. PT-141 has a well-characterized benefit-risk profile supported by over 1,200 patients in randomized trials, FDA review, and post-marketing surveillance data accumulated since 2019 1. AOD-9604 has promising preclinical biology but a failed human efficacy trial and no regulatory stamp of approval.

This does not mean AOD-9604 is ineffective. It means the evidence is not yet strong enough to make that claim with confidence. As Dr. John Kopchick, a co-discoverer of the growth hormone receptor and emeritus professor at Ohio University, has noted regarding hGH-derived peptides: "Fragments of growth hormone may retain specific biological activities, but each must be validated independently in controlled human studies before clinical claims are appropriate" 6.

Patients choosing AOD-9604 should understand they are accepting a higher degree of uncertainty. Patients choosing PT-141 should understand they are accepting a 40% chance of first-dose nausea in exchange for a validated 14-percentage-point improvement in clinically meaningful desire outcomes over placebo.